Dilacor XR Articles

Danger from same brand names for different drugs

7 February 2005

Aventis and Watson settle over Dilacor

28 September 2001

SkyePharma passes credibility test, with profitability aim soon to be

18 January 2001

Andrx Submits ANDA For Bioequivalent Drugs

23 September 1998

SkyePharma Benefits From Lilly Trial Advance

15 May 1998

FDA Advisory C'tee Recommendation For R-PR's Lovenox

3 July 1997

R-PR Posts Profits Climb But Flat Turnover In First Half

5 August 1996

R-PR Gets US Approval For Nasacort AQ

16 October 1995

NEW YORK STOCK COMMENT

22 May 1995

Watson Offers $606.5 Million For Circa

10 April 1995

Calcium Channel Blockers Raise Heart Attack Risk?

20 March 1995

Diltiazem Dispute

27 February 1995

1994 Transitional For R-PR With Better Second Half

6 February 1995

Second Launch Of Jago Geomatrix System

15 August 1994

RHONE-POULENC RORER '93 RESULTS BELOW EXPECTATIONS

7 February 1994

STRONG FIRST QUARTER FOR R-PR

26 April 1993

RHONE-POULENC RORER NET INCOME UP 13.4%

2 November 1992

R-PR'S DILACOR XR APPROVED IN USA

8 June 1992

Showing 1-18 of 18 articles

Go to beginningPrevious
  • 1
NextGo to end